9th October 2023
AACR OVARIAN CANCER CONFERENCE PRESENTATION
• Data from preclinical studies in ovarian cancer presented at premier international conference in
Boston, USA.
• Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer
• Data from these studies support clinical study of narmafotinib in ovarian cancer – with plans now commencing with leading international cancer specialists
I’m guessing it is something to do with this conference ...
.
- Forums
- ASX - By Stock
- ATX
- Ann: Pause in Trading
Ann: Pause in Trading, page-5
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
|
|||||
Last
6.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.67M |
Open | High | Low | Value | Volume |
6.4¢ | 6.4¢ | 6.1¢ | $9.419K | 149.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 39253 | 6.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.1¢ | 12705 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 39253 | 0.060 |
3 | 77817 | 0.059 |
3 | 100991 | 0.058 |
2 | 62105 | 0.057 |
1 | 78520 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.061 | 12705 | 1 |
0.070 | 12509 | 2 |
0.075 | 335646 | 1 |
0.079 | 3000 | 1 |
0.080 | 200000 | 1 |
Last trade - 15.59pm 22/07/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |